Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

With IP from a Yale lab, Simcha hopes its IL-18 variant will circumvent a resistance mechanism in tumors

Simcha emerged Wednesday with $25 million in series A funding to bring its lead product, a variant of IL-18 designed to thwart a resistance mechanism in tumors, through Phase I testing.

The corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) led Simcha Therapeutics’ financing, which closed in May. Other investors included Sequoia Capital China and Connecticut Innovations. WuXi’s Lennart Lee and Sequoia’s

Read the full 645 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE